Half-year report · Q2
3034.TEDINET S100URNY
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥124.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥180.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥88.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥6.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥9.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥1.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥137.3bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥117.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥107.4bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥79.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥64.9bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥58.0bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥52.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥50.3bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥27.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥477m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥265m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥32.43 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥131.11 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.8 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥686m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥64m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.4bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥622m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥928m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥33.9bn |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.7bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥125.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥124.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥686m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥7.9bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥237m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥237m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥81.0bn |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥63m |
| jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥173m |
| jpcrp040300-q2r_E03476-000Medical Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥801m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥897m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥897m |
| jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥142m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥88.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥88.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥237m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥5.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 543
| Item | Context | Value | Unit |
|---|---|---|---|
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行(信託口) | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)東京都中央区晴海一丁目8番12号 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)第一三共株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋本町三丁目5番1号 | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)株式会社メディパル保険サービス | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)兵庫県神戸市中央区磯辺通三丁目1番7号 | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)中村商事株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)東京都品川区 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)一単元(100株)未満の株式 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)クオールホールディングス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都港区虎ノ門四丁目3番1号城山トラストタワー37階 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |